News Nine more companies sign pricing deals with Trump Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.
News UK, US approve GSK's twice-yearly asthma drug GSK scores a first approval in the UK for new severe asthma and CRSwNP therapy Exdensur, but a second in the US covers the asthma indication only.
News GSK closes on approval of asthma hope depemokimab GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.
News CHMP decision levels the playing field for GSK's RSV jab GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.
News GSK unit and AnaptysBio trade lawsuits over Jemperli A spat between GSK/Tesaro and AnaptysBio over cancer drug Jemperli has escalated into litigation, with both parties claiming breach of contract.
News GSK pumps £45m into antimicrobial resistance projects GSK has revealed the six projects it will fund with the Fleming Initiative on antimicrobial resistance, set up with Imperial College London last year.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.